Injected immune therapy for head and neck cancer
Treatments studied
Part of Cancer, Mouth & dental clinical trials.
This trial tests an experimental treatment that is injected directly into the tumor to stimulate your immune system to fight the cancer. It is for people with head and neck cancer who have not been helped by prior treatments or who are scheduled for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be diagnosed with head and neck cancer that either can't be removed with surgery, has come back, or has spread. (You may also qualify if your tumor is scheduled for surgery.)
- You must have already received at least one prior cancer treatment, such as chemotherapy, a targeted therapy, or immunotherapy (like a PD-1 or PD-L1 inhibitor).
- Your tumor must be at least 1 cm in size and safely reachable for a direct injection.
- You should be in fairly good health, able to care for yourself (ECOG 0-1), with adequate blood counts and liver function.
- If you could become pregnant or father a child, you must agree to use two forms of effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment where a specially designed virus carrying an anti-cancer gene is injected directly into tumors in the head and neck area. It's for patients whose cancer has come back or spread after prior chemotherapy and who cannot have surgery or radiation.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.
This trial tests a new immunotherapy drug called volrustomig for people with advanced head and neck cancer that is not caused by HPV. The goal is to see if giving this treatment based on how the cancer responds can help shrink tumors or stop them from growing.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.